Drug intelligence / Profile preview

CMTS4520 (The Second Affiliated Hospital of Nanjing Medical University)

Development stage: Unknown
Lead developer: The Second Hospital of Nanjing Medical University
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

CMTS4520 is an investigational combination therapy comprising dietary fiber and probiotics, developed by The Second Affiliated Hospital of Nanjing Medical University. It is specifically being evaluated for the treatment of chronic diarrhea in adults. The mechanism of action involves the modulation of the intestinal microbiota and the improvement of bowel movement frequency and stool consistency through the synergistic effects of prebiotics (fiber) and probiotic microorganisms. It is currently in Phase 1/2 clinical trials.

Other names: Dietary Fiber Probiotics

Beyond the preview

Go deeper on CMTS4520 (The Second Affiliated Hospital of Nanjing Medical University).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMTS4520 (The Second Affiliated Hospital of Nanjing Medical University).

Explore the full profile